Page 29 - P4304.1-V96_PS-Magazine-April 2024

PSUK

OFFER

A simple choice

for bone health...

Maximising your savings with Accrete-D !
3

Accrete-D3 Film-coated Tablets Accrete-D3 One-a-Day Chewable Tablets

Pack Size: 60 Pack Size: 30
PIP Code: 366-8969 PIP Code: 405-6008
NHS Price: £2.95 NHS Price: £2.95

Net Price: £2.36 Net Price: £2.36
PROFIT: £0.59 PROFIT: £0.59
PSUK Discount: 20% PSUK Discount: 20%
(10% MDS + 10% wholesale) (10% MDS + 10% wholesale)
SWALLOWABLE CHEWABLE

ONE-A-DAY

NHS list price: Drug Tariff February 2021.

Abbreviated Prescribing Information.
®
Accrete D One-a-Day 1000 mg/880 IU Chewable Tablets & Accrete D Film-Coated Tablets ® insufficiency. This medicinal product contains aspartame (E951), a source of phenylalanine
3
3
Abbreviated Prescribing Information. Please refer to the appropriate Summary of Product which may be harmful for people with phenylketonuria. Interactions: Thiazide diuretics, cardiac
Characteristics (SmPC) before prescribing Accrete D . Accrete D One-a-Day 1000 mg/880 glycosides, systemic corticosteroids, phenytoin, barbiturates, ion exchange resins, laxatives. Do
3
3
IU Chewable Tablets : Each chewable tablet contains 1000 mg calcium (as 2500 mg calcium not take calcium within 2 hours of eating foods high in oxalic acid and phytic acid. Administer
®
carbonate) and 880 IU colecalciferol. Contains aspartame (E951), sorbitol (E420), isomalt (E953) tetracycline <2 hours before or 4 to 6 hours after Accrete D 3 . Administer bisphosphonate or
and sucrose. Accrete D Film-Coated Tablets : Contains 600 mg calcium (as calcium carbonate sodium fluoride at least 3 hours before Accrete D . Do not use levothyroxine within 4 hours
®
3
3
1500 mg) and 10 micrograms of colecalciferol (equivalent to 400 IU vitamin D ) and sucrose. before or after Accrete D . Administer quinolone antibiotics <2 hours before or 6 hours after
3
3
Indication: Prevention and treatment of vitamin D and calcium deficiency in the elderly. Adjunct Accrete D . Pregnancy and Lactation: During pregnancy, daily dose should not exceed 1500
3
to specific osteoporosis treatment of patients at risk of vitamin D and calcium deficiency. mg calcium and 600 IU vitamin D. Halve tablet if necessary to reduce dose. Suitable for use
Dosage and Administration: For oral use. Accrete D One-a-Day: One chewable tablet daily. during breastfeeding. Calcium and vitamin D pass into breast milk. This should be considered
3
Accrete D Film-Coated: One tablet twice per day. Contraindications: Hypersensitivity to any when giving additional vitamin D to the child. Undesirable effects: Allergic reactions may be
3
of the ingredients, hypercalciuria/hypercalcaemia and conditions leading to hypercalciuria/ possible. Uncommonly hypercalcaemia or hypercalciuria. Rarely gastro-intestinal disorders, rash,
hypercalcaemia, nephrolithiasis, nephrocalcinosis, hypervitaminosis D, severe renal impairment/ pruritus, urticaria. Legal Category: Accrete D One-a-Day: P; Accrete D Film-Coated: P. Pack
3
3
renal failure. Not for paediatric use. Warnings and Precautions: Monitor serum calcium and size: Accrete D One-a-Day: £2.95 for 30 tablets; Accrete D Film-Coated: £2.95 for 60 tablets.
3
3
creatinine (renal function) in cases of long-term use, concomitant use of cardiac glycosides MA Number: Accrete D One-a-Day: PL04416/1318; Accrete D Film-Coated: PL 40861/0001.
3
3
or thiazide diuretics, or a high tendency to calculus formation. Use caution and monitor Distributor (Accrete One-a-Day)/MA Holder (Accrete D Film-Coated): Internis Pharmaceuticals
3
calcium and phosphate in cases of renal impairment. In cases of hypercalcaemia or impaired Ltd., Linthwaite Laboratories, Linthwaite, Huddersfield, HD7 5QH, UK. Date of preparation:
renal function, reduce the dose or discontinue treatment. Use caution in cases of sarcoidosis, August 2020. Unique ID: ACC-131. ACC-135. DoP: Jan 2021
immobilised patients with osteoporosis. In patients with a history of renal stones, hypercalciuria
should be excluded. Use close medical supervision if prescribing additional calcium or vitamin Adverse events should be reported. Reporting forms and information can be found at:
D via other medicines. Concomitant use of tetracyclines or quinolones is not recommended. Do www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or
not take in case of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase Apple App Store. Adverse events should also be reported to 01484 848164.
For more information contact us on 01484 842 217 or email
bonehealth@thorntonross.com or visit www.thorntonross.com
29
or call us on 01904 558 350 MDS Terms Information | PS Magazine 29